Influx Healthtech Q1 Results FY27: Date, Revenue Estimates, Key Catalysts and Share Price Target

Influx Healthtech CMP Rs.293. Market cap Rs.712 Cr. PE Not meaningful. 12-month target Rs.296-334.

Updated: 8 Jul 2026 • 6:21 pm

Posted by:

Influx Healthtech Q1 Results FY27: Date, Revenue Estimates, Key Catalysts and Share Price Target

Influx Healthtech Q1 Results FY27 is coming into focus as investors position ahead of the July-August 2026 results season, with Influx Healthtech shares trading at Rs.293 against a market capitalisation of Rs.712 Cr and a price-to-earnings multiple of Not meaningful. As a pharmaceuticals and life sciences name on the NSE and BSE, Influx Healthtech enters the Influx Healthtech Q1 Results FY27 print with the Street watching revenue momentum, margin trajectory and management commentary on FY27 guidance.

Quarterly financials for Influx Healthtech are not yet fully available on Univest’s data partners for this cycle; investors should track Screener.in and the NSE/BSE filings directly for the Influx Healthtech Q1 Results FY27 result date and cross-check any figures before making investment decisions.

Get Free Investment Predictions and Influx Healthtech Research at Univest

Influx Healthtech (NSE: INFLUX) operates in the pharmaceuticals and life sciences space and is tracked on Univest under its NSE and BSE listings ahead of the Influx Healthtech Q1 Results FY27 season, forming the base against which the Influx Healthtech Q1 Results FY27 estimates in this article are built. This Influx Healthtech Q1 Results FY27 snapshot is intended as a starting point for research, not a substitute for the company’s own disclosures.

Table of Contents

Influx Healthtech Q1 FY27 Estimates

Metric	Detail
CMP	Rs.293
Market Cap	Rs.712 Cr
Results Date	July-August 2026 (indicative)
12-Month Target (Uniresearch Estimate)	Rs.296-334

Univest, a SEBI-Registered Investment Advisor, Tracks Influx Healthtech Ahead of Q1 FY27 Results

Key Catalysts to Watch

1. CDMO Pipeline Visibility

Steady traction in the CDMO and contract manufacturing pipeline supporting revenue visibility is one of the primary variables that analysts are tracking ahead of Influx Healthtech’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Influx Healthtech share price target or faces renewed pressure.

2. New Product Approvals

New product approvals and launches adding to the domestic and export portfolio is one of the primary variables that analysts are tracking ahead of Influx Healthtech’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Influx Healthtech share price target or faces renewed pressure.

3. Capacity Scale-Up

Operating leverage from scale-up in recently commissioned manufacturing capacity is one of the primary variables that analysts are tracking ahead of Influx Healthtech’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Influx Healthtech share price target or faces renewed pressure.

Download the Univest iOS App or Univest Android App to track Influx Healthtech’s live price and Q1 FY27 result updates.

Key Risks to the Influx Healthtech Q1 Results FY27 Outlook

Pricing pressure in key export markets, particularly the US generics segment.
Regulatory or plant compliance issues affecting supply continuity.
R&D and capacity expansion costs weighing on near-term profitability.

Recent Performance Context

Detailed recent-quarter financials for Influx Healthtech were not available from Univest’s data partners at the time of writing. Investors should check Screener.in or the company’s exchange filings for the latest verified numbers before the Q1 FY27 results.

Technical Analysis Ahead of Influx Healthtech Q1 Results FY27

Influx Healthtech shares last traded at Rs.293. For the current 52-week high and low, support and resistance levels, investors should check the live chart on the Univest app or the NSE website, since these levels move intraday and are not reproduced here to avoid stale data.

Share Price Target Based on the Influx Healthtech Q1 Results FY27 Outlook

3-6 Month Target

Over a 3-6 month horizon, the Influx Healthtech Q1 Results FY27 trailing-growth framework points to a range of Rs.287-311 for Influx Healthtech, contingent on the Influx Healthtech Q1 Results FY27 print matching or beating the trailing growth trend.

12-Month Target

The 12-month target (Uniresearch estimate) tied to this Influx Healthtech Q1 Results FY27 view for Influx Healthtech works out to Rs.296-334, built on the same trailing revenue growth trend and current valuation multiple. Tracking is how Univest research categorises the stock heading into Influx Healthtech Q1 Results FY27, not a formal Buy or Sell call.

FY27-28 Outlook

Looking out to FY27-28, a sustained continuation of the growth trajectory implied by this Influx Healthtech Q1 Results FY27 analysis would put Influx Healthtech in a Rs.312-365 range, though this is sensitive to sector-wide demand, cost trends and any change in the company’s competitive position.

What to Watch in the Influx Healthtech Q1 Results FY27 Print

Revenue and PAT versus the Influx Healthtech Q1 Results FY27 estimate range in this preview.
Management commentary on FY27 growth guidance and margin trajectory relevant to the Influx Healthtech Q1 Results FY27 narrative.
Steady traction in the CDMO and contract manufacturing pipeline supporting revenue visibility
Pricing pressure in key export markets, particularly the US generics segment

Conclusion on Influx Healthtech Q1 Results FY27

Influx Healthtech enters the Q1 FY27 results season trading at Rs.293, with the 12-month Uniresearch target range of Rs.296-334 reflecting a tracking stance. Investors tracking the Influx Healthtech Q1 Results FY27 print should watch the catalysts and risks above and consult a SEBI-registered advisor before making investment decisions around the results.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

FAQs on Influx Healthtech Q1 Results FY27

When are Influx Healthtech Q1 FY27 results expected?

Ans. Influx Healthtech’s Q1 FY27 results are expected in the July-August 2026 window, in line with the broader NSE and BSE results season for the quarter ending June 2026.

What is the Influx Healthtech Q1 FY27 revenue estimate?

Ans. Detailed quarterly estimates are not available for Influx Healthtech at this time; check Screener.in or the company’s exchange filings for verified numbers.

What is the Influx Healthtech share price target?

Ans. The 12-month Uniresearch estimate for Influx Healthtech share price target is Rs.296-334, based on trailing growth and current valuation multiples.

Is Influx Healthtech a good buy before Q1 FY27 results?

Ans. Influx Healthtech is tracking heading into Q1 FY27 results. Investors should weigh the catalysts and risks in this article and consult a SEBI-registered advisor before investing.

What should investors watch in Influx Healthtech’s Q1 FY27 results?

Ans. Key items include revenue and PAT versus estimates, management commentary on FY27 guidance, and steady traction in the CDMO and contract manufacturing pipeline supporting revenue visibility.